UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/522,106	07/26/2007	Karl-Heinz Kogel	12810-00067-US	9243
	7590 08/03/201 SOVE LODGE & HUT	EXAMINER		
PO BOX 2207		IBRAHIM, MEDINA AHMED		
WILMINGTON, DE 19899			ART UNIT	PAPER NUMBER
		1638		
			MAIL DATE	DELIVERY MODE
			08/03/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/522,106	KOGEL ET AL.	
Examiner	Art Unit	
Medina A. Ibrahim	1638	

	Medina A. Ibrahim	1036	
The MAILING DATE of this communication appe	ars on the cover sheet with the c	correspondence add	ress
THE REPLY FILED <u>01 July 2010</u> FAILS TO PLACE THIS APPL	ICATION IN CONDITION FOR AL	LOWANCE.	
 The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 C periods: 	replies: (1) an amendment, affidavit eal (with appeal fee) in compliance	t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
a) The period for reply expires <u>3</u> months from the mailing date	of the final rejection.		
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire la	dvisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing	date of the final rejection	n.
Examiner Note: If box 1 is checked, check either box (a) or (MONTHS OF THE FINAL REJECTION. See MPEP 706.07(1) Extensions of time may be obtained under 37 CFR 1.136(a). The date	f).		
have been filed is the date for purposes of determining the period of ext under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the s set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b).	ension and the corresponding amount of hortened statutory period for reply original controls.	of the fee. The appropria nally set in the final Offic	ate extension fee e action; or (2) as
NOTICE OF APPEAL	l'anna 1950 OZ OED 44 OZ maratha	71 - d - 10-2- (0-	6 (- (6
 The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed with 	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
AMENDMENTS			
 The proposed amendment(s) filed after a final rejection, t (a) They raise new issues that would require further cor 			cause
(b) They raise the issue of new matter (see NOTE below	• •		
(c) They are not deemed to place the application in bet appeal; and/or	ter form for appeal by materially rec	lucing or simplifying tl	ne issues for
(d) ☐ They present additional claims without canceling a c	corresponding number of finally reje	cted claims.	
NOTE: (See 37 CFR 1.116 and 41.33(a)).			
4. $oxedsymbol{oxed}$ The amendments are not in compliance with 37 CFR 1.12		mpliant Amendment (I	PTOL-324).
5. 🔲 Applicant's reply has overcome the following rejection(s):			
 Newly proposed or amended claim(s) would be all non-allowable claim(s). 	·	-	-
7. For purposes of appeal, the proposed amendment(s): a) [how the new or amended claims would be rejected is prov The status of the claim(s) is (or will be) as follows: Claim(s) allowed:		l be entered and an e	xplanation of
Claim(s) allowed: Claim(s) objected to:			
Claim(s) rejected: <u>1-23</u> .			
Claim(s) withdrawn from consideration:			
AFFIDAVIT OR OTHER EVIDENCE			
 The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e). 			
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appea	ıl and/or appellant fail:	s to provide a
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER			
11. The request for reconsideration has been considered but See Continuation Sheet.	t does NOT place the application in	condition for allowan	ce because:
12. Note the attached Information <i>Disclosure Statement</i> (s).	PTO/SB/08) Paper No(s).		
13. 🛮 Other: See Continuation Sheet.	, , , , , , , , , , , , , , , , , , , ,		
	/Medina A Ibrahim/ Primary Examiner, Art U	nit 1638	
	i fillary Examiner, Art O	int 1000	

Continuation of 11. does NOT place the application in condition for allowance because: Applicant's arguments regarding the 112 1st rejection are duplicatives of what have been previously addressed. The amendment to claim 1 would not obviate the rejection because the scope of the claims is not commensurate with the scope of the enabling disclosure. The specification does not provide an enablemnt support for sequences comprising sense, antisense or dsRNA of any NADPH oxidase encoding sequence that is capable of reducing the content, activity and function of an endogenous NADPH oxidase gene, and hence induce increased resistance to plant pathogens. The specification also does not provide an enabling disclosure for sequences that are functional equivalent of exemplified or non-exemplified sequences or sequences having 50% to exemplified or non-exemplified sequences and capable of reducing activity, content, and function of an endogenous NADPH oxidase sequence when expressed in sense, antisense or dsRNA orientation in a transgenic plant, and hence increase pathogen resistance in the transgenic plant. Applicant provides no evidence to support the broad scope of the claims.

Continuation of 13. Other: The claims may be amended to recite dsRNA comprising SEQ ID NO: 1, transgenic plants comprising said dsRNA, and a method of introducing said dsRNA into a transgenic plant to increase pathogen resistance.